PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding PMV Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 74 | 70 | −4 |
| Shares | 39.0M | 39.0M | −64.7K (−0.2%) |
| Value | $58.2M | $58.8M | +$680.0K (+1.2%) |
New holders (6)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stonepine Capital Management, LLC | 535,805 | $809.1K | 0.65% |
| Peapod Lane Capital LLC | 445,744 | $673.1K | 0.67% |
| Velan Capital Investment Management LP | 35,000 | $52.9K | 0.05% |
| R Squared Ltd | 13,300 | $20.1K | 0.02% |
| Jones Financial Companies LLLP | 1,000 | $1.51K | 0.00% |
| BNP Paribas Arbitrage, SA | 763 | $1.15K | 0.00% |
Sold out (10)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Personal Cfo Solutions, LLC | 550,342 | $820.0K |
| Acuitas Investments, LLC | 440,687 | $656.6K |
| Gsa Capital Partners LLP | 73,352 | $109.0K |
| Susquehanna International Group, LLP | 44,160 | $65.8K |
| Virtu Financial LLC | 28,146 | $42.0K |
| Qube Research & Technologies Ltd | 26,257 | $39.1K |
| Amundi | 26,182 | $38.9K |
| HarbourVest Partners LLC | 11,533 | $17.2K |
| Catalyst Funds Management Pty Ltd | 2,100 | $3.13K |
| Nordwand Advisors, LLC | 2,000 | $2.98K |